TG02 / IOVaxis, Circio Holding - LARVOL DELTA

A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer. (PubMed, Heliyon) - P1 | "Low numbers limit conclusive clinical outcome reporting. High PD-1 expression on post-treatment TILs encourages the addition of an immune checkpoint inhibitor to TG02 and potentially other studies of peptide vaccines in future studies."

IO biomarker • Journal • Colorectal Cancer • Immunology • Oncology • Solid Tumor • CSF2 • KRAS • RAS

TG01 IND application filed in China by Circio’s partner IOVaxis Therapeutics (Circio Press Release) - "Circio Holding ASA...announces that partner IOVaxis Therapeutics of Nantong, China, has filed the updated TG01 investigational new drug (IND) application with the Chinese National Medical Products Administration (NMPA), with an expected review period of sixty days. IOVaxis has an exclusive option agreement to license mutant RAS cancer vaccines TG01 and TG02 for China, Hong Kong, Macau, and Singapore...Within two weeks of TG01 IND approval by the NMPA, IOVaxis may exercise its exclusive license option and trigger a USD 3m milestone payment to Circio....'Once we have the IND approval, we intend to initiate a phase 1 study in pancreatic cancer as soon as possible, and then rapidly expand to other KRAS indications and combinations'."

Licensing / partnership • New P1 trial • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor